On 19 November, Corriere della Sera reported, and Reuters confirmed, that L'Oréal is in talks to buy about 10% of Giorgio Armani, and EssilorLuxottica up to 5%. LVMH, the third company the founder named in his will as a preferred buyer, has dropped out. Armani is advised by Rothschild. Negotiations are well under way, but no deal has been signed, and the deadline set by the will falls in early March 2027. The headline is that Armani is selling its first stake to outsiders. The more revealing fact is who is buying. L'Oréal has made Armani's perfume and make-up since 1988. EssilorLuxottica makes its glasses. The first outside shareholders of one of the last great independent Italian fashion houses may be the two companies that already make a large share of the Armani products the world actually buys.
PART I: WHAT THE MARKET IS SHOWING
The will. Giorgio Armani died in September 2025. According to reports on the will, the heirs must sell around 15% of the company between 12 and 18 months after his death, preferably to L'Oréal, EssilorLuxottica or LVMH, without ruling out another player "of equal standing". A second sale of 30% to 54.9% may follow within three to five years, or the company may be listed on the stock market instead, within three to eight years of his death. The Giorgio Armani Foundation is set to keep at least 30% of the capital. The heirs were reported this month to favour an eventual listing over a sale to a large group, and may split the first stake "so that no single strategic investor gains an advantage". Chief executive Giuseppe Marsocci had already said in September: "It is not written in stone that it has to be one investor."
The price. Bankers and advisers cited by the press value Armani at between 5 and 7 billion euros. On that range, 15% is worth roughly 750 million to 1.05 billion euros, L'Oréal's 10% roughly 500 to 700 million, and EssilorLuxottica's 5% roughly 250 to 350 million. Earlier analyst estimates were wider, from 5 to 12 billion euros. No price has been agreed.
The company. In its first results after the founder's death, published in April, Armani reported 2025 revenue of 2.19 billion euros, down 2.8% at constant exchange rates, weighed by weak wholesale. Core EBITDA rose 3.2% to 152.7 million euros and operating profit rose 2% to 52.6 million. Including direct sales by its licensees, Armani put total turnover at about 4 billion euros. Marsocci warned of "a possible structural change in the approach to luxury".
The licences. L'Oréal has developed Armani fragrance, skincare and make-up since 1988. In March 2018 the two companies extended the licence to 2050. In 2017 the business already generated more than a billion euros of revenue for L'Oréal; Corriere now puts it at about 1.3 billion euros a year. EssilorLuxottica's eyewear agreement with Armani was renewed in 2023 for 15 years and runs until 2037.
The precedent. L'Oréal has done this before, on a larger scale. On 31 March 2026 it completed the purchase of Kering Beauté for about 4 billion euros, including House of Creed and 50-year exclusive licences for Bottega Veneta and Balenciaga. It also secured the right to a 50-year licence for Gucci beauty, which begins when Gucci's existing licence with Coty expires.
The evidence against the obvious story. Several facts complicate the reading. Nothing is signed, and the stakes, the price and even the list of buyers could change. LVMH's exit may be about price rather than strategy: the only explanation reported is that it "had less appetite for a deal". L'Oréal's licence already runs until 2050, so it does not need equity to keep making Armani perfume for another 24 years. Armani is not in distress: revenue slipped, but core profit rose. And the heirs prefer a listing for the second stage, so neither licensee may ever get close to control.
PART II: WHAT THE MARKET IS NOT SAYING
The licensees are a large part of what Armani is. Armani's own revenue was 2.19 billion euros in 2025; its turnover including licensees was about 4 billion. On the company's own figures, roughly 1.8 billion euros of Armani-branded sales, close to half the total, are made by other companies. L'Oréal's Armani beauty business alone, at about 1.3 billion euros a year, is equivalent to around 60% of the fashion house's own revenue. For many people around the world, Armani is a fragrance bottle or a pair of glasses, not a jacket. The two companies at the table are the ones that make that Armani.
Why a licensee buys equity: the Gucci lesson. If L'Oréal's licence runs until 2050, why buy shares at all? The answer sits in L'Oréal's own Kering deal. Coty has made Gucci fragrance for years under licence. When Kering chose a new partner, it did not need to break that licence: it simply agreed that L'Oréal would take over Gucci beauty for 50 years once Coty's licence expires. A licence protects a business only until its end date and only as long as the brand owner's priorities stay the same. Equity gives a seat in the room where those priorities are set. For EssilorLuxottica, whose agreement ends in 2037, that seat is worth more than for L'Oréal. And Armani's second stage, a further 30% to 54.9% within three to five years, means the owner of Armani in the 2030s is not yet known. A licensee that already holds shares will be in the room when it is decided.
Why the heirs would welcome them. For the heirs, licensees are unusually safe partners. Their business depends on Armani staying exactly what it is: a coherent, desirable name that sells perfume and eyewear around the world. They have no reason to turn it into something else, and with stakes of 10% and 5%, split between two companies, neither gains control. LVMH, the only fashion group on the founder's list, would have been a different kind of shareholder: a potential future owner with its own perfume and eyewear businesses. Its exit makes the first stage look less like the start of a sale and more like a way of protecting independence while meeting the terms of the will.
A framework: the tenants are buying the building. In our analysis of Formula 1 and luxury, we described a landlord, who owns the audience, and tenants, who pay to be close to it. Licensing works the same way: the brand owner is the landlord, the licensees are tenants who pay royalties to use the name. What Armani shows is the next step in that economy. When the landlord's future is uncertain, the most valuable tenants buy a share of the building. For an executive, three questions follow:
- Dependency: what share of the brand's total turnover is made by licensees rather than the house itself?
- Duration: when do the key licences end, and who decides on their renewal?
- Alignment: which shareholders would protect the brand as it is, and which would want to change it?
PART III: WHAT COMES NEXT
The emerging scenario. By March 2027, Armani has a new shareholder structure in which the Foundation keeps control, L'Oréal and EssilorLuxottica hold minority stakes, and the question of the second stage, a larger sale or a listing, moves to the end of the decade. Armani remains independent, but with its two largest partners inside the company.
Who else this concerns. Other founder-owned houses facing succession now have a model: sell minority stakes to the partners who already depend on the brand, rather than to a group that may want to absorb it. Licensees without equity are exposed: Coty's position at Gucci shows how a long relationship can end when the brand owner chooses a different partner. And L'Oréal's pattern becomes clearer: long-dated rights to the names of fashion's largest houses, from Armani to 2050 to Bottega Veneta and Balenciaga for 50 years, now possibly reinforced by equity.
What could prove this wrong. A fashion group joining the first stage, which would mean the sale is about the fashion house rather than the licences. A price far above the reported range, which would suggest buyers see a path to control. The heirs abandoning the listing route in favour of selling the second stage to one of the licensees. Or the deal collapsing before March, forcing a different buyer under the "equal standing" clause.
What to watch over the next 12 to 24 months.
The signing, the final split between L'Oréal and EssilorLuxottica, and the valuation; whether any governance rights come with the stakes; Armani's 2026 results in the spring; the renewal timetable of EssilorLuxottica's licence before 2037; the expiry of Coty's Gucci licence and the handover to L'Oréal; and any signal on the timing of a listing.
THE WESHMIND VERDICT
The most important thing about Armani's first sale might not be who is buying. It might be what they are buying: not control of a fashion house, but insurance on the licences that already make them money. The evidence supports that reading, with the caution that nothing is signed. Nearly half of Armani's turnover is made by licensees; the largest of them has just shown at Gucci what a licence is worth when the brand owner chooses someone else; and the only fashion group on the founder's list has stepped aside. In the succession wave now facing fashion's founder-owned houses, the most natural buyers may not be the conglomerates. They may be the tenants, buying a share of the building they have lived in for decades.






